APOE and early-onset autosomal dominant Alzheimer disease: This includes strategies advocating for personalized Alzheimer’s disease treatments based on identified neurotransmitter and ion modulations [230], as well as examining the influence of APOE4 on the development of both Alzheimer’s and SARS-CoV-2 [231], alongside neuroimaging biomarkers that were identified in individuals who have recovered from COVID-19 [232].